349 related articles for article (PubMed ID: 24997741)
1. Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis.
Paccou J; Wendling D
Joint Bone Spine; 2015 Mar; 82(2):80-5. PubMed ID: 24997741
[TBL] [Abstract][Full Text] [Related]
2. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.
Ash Z; Gaujoux-Viala C; Gossec L; Hensor EM; FitzGerald O; Winthrop K; van der Heijde D; Emery P; Smolen JS; Marzo-Ortega H
Ann Rheum Dis; 2012 Mar; 71(3):319-26. PubMed ID: 21803753
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
Ramiro S; Smolen JS; Landewé R; van der Heijde D; Dougados M; Emery P; de Wit M; Cutolo M; Oliver S; Gossec L
Ann Rheum Dis; 2016 Mar; 75(3):490-8. PubMed ID: 26660203
[TBL] [Abstract][Full Text] [Related]
4. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
Pham T; Fautrel B; Dernis E; Goupille P; Guillemin F; Le Loët X; Ravaud P; Claudepierre P; Miceli-Richard C; de Bandt M; Breban M; Maillefert JF; Masson C; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Combe B;
Joint Bone Spine; 2007 Dec; 74(6):638-46. PubMed ID: 18065252
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Dougados M; de Wit M; Primdahl J; McInnes I; van der Heijde D; Baraliakos X; Falzon L; Gossec L
Ann Rheum Dis; 2020 Jun; 79(6):778-786. PubMed ID: 32381564
[TBL] [Abstract][Full Text] [Related]
6. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Gossec L; Smolen JS; Ramiro S; de Wit M; Cutolo M; Dougados M; Emery P; Landewé R; Oliver S; Aletaha D; Betteridge N; Braun J; Burmester G; Cañete JD; Damjanov N; FitzGerald O; Haglund E; Helliwell P; Kvien TK; Lories R; Luger T; Maccarone M; Marzo-Ortega H; McGonagle D; McInnes IB; Olivieri I; Pavelka K; Schett G; Sieper J; van den Bosch F; Veale DJ; Wollenhaupt J; Zink A; van der Heijde D
Ann Rheum Dis; 2016 Mar; 75(3):499-510. PubMed ID: 26644232
[TBL] [Abstract][Full Text] [Related]
7. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Singh JA; Guyatt G; Ogdie A; Gladman DD; Deal C; Deodhar A; Dubreuil M; Dunham J; Husni ME; Kenny S; Kwan-Morley J; Lin J; Marchetta P; Mease PJ; Merola JF; Miner J; Ritchlin CT; Siaton B; Smith BJ; Van Voorhees AS; Jonsson AH; Shah AA; Sullivan N; Turgunbaev M; Coates LC; Gottlieb A; Magrey M; Nowell WB; Orbai AM; Reddy SM; Scher JU; Siegel E; Siegel M; Walsh JA; Turner AS; Reston J
Arthritis Rheumatol; 2019 Jan; 71(1):5-32. PubMed ID: 30499246
[TBL] [Abstract][Full Text] [Related]
8. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis.
Wendling D; Lukas C; Prati C; Claudepierre P; Gossec L; Goupille P; Hudry C; Miceli-Richard C; Molto A; Pham T; Saraux A; Dougados M
Joint Bone Spine; 2018 May; 85(3):275-284. PubMed ID: 29407043
[TBL] [Abstract][Full Text] [Related]
9. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.
Gossec L; Coates LC; de Wit M; Kavanaugh A; Ramiro S; Mease PJ; Ritchlin CT; van der Heijde D; Smolen JS
Nat Rev Rheumatol; 2016 Dec; 12(12):743-750. PubMed ID: 27829672
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
Kawalec P; Holko P; Moćko P; Pilc A
Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A; Smolen JS; Ferreira RJO; Bertheussen H; Baraliakos X; Aletaha D; McGonagle DG; van der Heijde D; McInnes IB; Esbensen BA; Winthrop KL; Boehncke WH; Schoones JW; Gossec L
Ann Rheum Dis; 2024 May; 83(6):760-774. PubMed ID: 38503473
[TBL] [Abstract][Full Text] [Related]
12. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).
Colebatch AN; Marks JL; Edwards CJ
Cochrane Database Syst Rev; 2011 Nov; (11):CD008872. PubMed ID: 22071858
[TBL] [Abstract][Full Text] [Related]
13. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Gossec L; Baraliakos X; Kerschbaumer A; de Wit M; McInnes I; Dougados M; Primdahl J; McGonagle DG; Aletaha D; Balanescu A; Balint PV; Bertheussen H; Boehncke WH; Burmester GR; Canete JD; Damjanov NS; Kragstrup TW; Kvien TK; Landewé RBM; Lories RJU; Marzo-Ortega H; Poddubnyy D; Rodrigues Manica SA; Schett G; Veale DJ; Van den Bosch FE; van der Heijde D; Smolen JS
Ann Rheum Dis; 2020 Jun; 79(6):700-712. PubMed ID: 32434812
[TBL] [Abstract][Full Text] [Related]
14. Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.
Goulabchand R; Mouterde G; Barnetche T; Lukas C; Morel J; Combe B
Ann Rheum Dis; 2014 Feb; 73(2):414-9. PubMed ID: 23355079
[TBL] [Abstract][Full Text] [Related]
15. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
Woolacott N; Bravo Vergel Y; Hawkins N; Kainth A; Khadjesari Z; Misso K; Light K; Asseburg C; Palmer S; Claxton K; Bruce I; Sculpher M; Riemsma R
Health Technol Assess; 2006 Sep; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: A meta-analysis.
Ungprasert P; Thongprayoon C; Davis JM
Semin Arthritis Rheum; 2016 Feb; 45(4):428-38. PubMed ID: 26610638
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
18. [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis].
Juanola Roura X; Zarco Montejo P; Sanz Sanz J; Muñoz Fernández S; Mulero Mendoza J; Linares Ferrando LF; Gratacós Masmitja J; García de Vicuña R; Fernandez Carballido C; Collantes Estevez E; Batlle Gualda E; Ariza Ariza R; Loza Santamaría E
Reumatol Clin; 2011; 7(2):113-23. PubMed ID: 21794794
[TBL] [Abstract][Full Text] [Related]
19. 2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis.
Wendling D; Hecquet S; Fogel O; Letarouilly JG; Verhoeven F; Pham T; Prati C; Molto A; Goupille P; Dernis E; Saraux A; Ruyssen-Witrand A; Lukas C; Miceli-Richard C; Hudry C; Richette P; Breban M; Gossec L; Dougados M; Claudepierre P
Joint Bone Spine; 2022 May; 89(3):105344. PubMed ID: 35038574
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
